JP2023548346A5 - - Google Patents
Info
- Publication number
- JP2023548346A5 JP2023548346A5 JP2023526553A JP2023526553A JP2023548346A5 JP 2023548346 A5 JP2023548346 A5 JP 2023548346A5 JP 2023526553 A JP2023526553 A JP 2023526553A JP 2023526553 A JP2023526553 A JP 2023526553A JP 2023548346 A5 JP2023548346 A5 JP 2023548346A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence described
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063112380P | 2020-11-11 | 2020-11-11 | |
| US63/112,380 | 2020-11-11 | ||
| US202063113922P | 2020-11-15 | 2020-11-15 | |
| US63/113,922 | 2020-11-15 | ||
| PCT/US2021/058181 WO2022103660A1 (en) | 2020-11-11 | 2021-11-05 | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023548346A JP2023548346A (ja) | 2023-11-16 |
| JP2023548346A5 true JP2023548346A5 (https=) | 2024-11-08 |
Family
ID=81601668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023526553A Pending JP2023548346A (ja) | 2020-11-11 | 2021-11-05 | アクチビン／ｔｇｆ－ベータおよびｒａｎｋｌの二機能性アンタゴニストならびにその使用 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4243931A4 (https=) |
| JP (1) | JP2023548346A (https=) |
| KR (1) | KR20230118573A (https=) |
| AU (1) | AU2021377176A1 (https=) |
| CA (1) | CA3197104A1 (https=) |
| MX (1) | MX2023005565A (https=) |
| WO (1) | WO2022103660A1 (https=) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL142900A0 (en) * | 1999-09-03 | 2002-04-21 | Amgen Inc | Compositions and methods for the prevention or treatment of cancer and bone loss associated with cancer |
| TR201901929T4 (tr) * | 2005-02-08 | 2019-03-21 | Genzyme Corp | TGFBeta'ya antikorlar. |
| CL2007002567A1 (es) * | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| KR20100058509A (ko) * | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| JP2011526792A (ja) * | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| EP2401296A1 (en) * | 2009-02-24 | 2012-01-04 | Glaxo Group Limited | Multivalent and/or multispecific rankl-binding constructs |
| EP2826789A1 (en) * | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP3202459B1 (en) * | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| AU2012375257B2 (en) * | 2012-03-31 | 2019-09-12 | R-Pharm International, Limited Liability Company | Osteoprotegerin derived composition and use thereof |
| CN105431453A (zh) * | 2012-11-01 | 2016-03-23 | 艾伯维公司 | 稳定的双重可变结构域免疫球蛋白制剂 |
| UY35148A (es) * | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| JP6594855B2 (ja) * | 2013-03-15 | 2019-10-23 | ゼンコア インコーポレイテッド | ヘテロ二量体タンパク質 |
| TW201920262A (zh) * | 2013-07-30 | 2019-06-01 | 美商再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| US20160075772A1 (en) * | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| US10227411B2 (en) * | 2015-03-05 | 2019-03-12 | Xencor, Inc. | Modulation of T cells with bispecific antibodies and FC fusions |
| EP3274457A4 (en) * | 2015-03-26 | 2018-08-08 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
| WO2018009732A1 (en) * | 2016-07-08 | 2018-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| WO2018026742A1 (en) * | 2016-08-01 | 2018-02-08 | Askgene Pharma Inc. | Novel antibody-albumin-drug conjugates (aadc) and methods for using them |
| SI4190355T1 (sl) * | 2017-04-28 | 2025-02-28 | Amgen Inc. | Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe |
| WO2019079762A1 (en) * | 2017-10-20 | 2019-04-25 | Children's National Medical Center | METHODS OF DISCOVERING ANTIBODIES USING TRANSCRIPTOMES AND COMPOSITIONS DERIVED THEREFROM |
| AU2019394364A1 (en) * | 2018-12-05 | 2021-06-17 | The Council Of The Queensland Institute Of Medical Research | Rank antagonists and uses therefor |
-
2021
- 2021-11-05 KR KR1020237019575A patent/KR20230118573A/ko active Pending
- 2021-11-05 WO PCT/US2021/058181 patent/WO2022103660A1/en not_active Ceased
- 2021-11-05 JP JP2023526553A patent/JP2023548346A/ja active Pending
- 2021-11-05 MX MX2023005565A patent/MX2023005565A/es unknown
- 2021-11-05 EP EP21892613.7A patent/EP4243931A4/en active Pending
- 2021-11-05 AU AU2021377176A patent/AU2021377176A1/en active Pending
- 2021-11-05 CA CA3197104A patent/CA3197104A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022515318A5 (https=) | ||
| JP2020510422A5 (https=) | ||
| JP2018523493A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2019513018A5 (https=) | ||
| JP2019116474A5 (https=) | ||
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| JP2022545660A5 (https=) | ||
| JP2019527553A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| JP2020513769A5 (https=) | ||
| WO2013044215A4 (en) | Vegf/dll4 binding agents and uses thereof | |
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2026041845A5 (https=) | ||
| WO2018119118A4 (en) | Lymphotoxin-beta receptor-binding agents, targeting antibodies, and uses thereof | |
| JP2023527937A5 (https=) | ||
| JP2021512604A5 (https=) | ||
| JP2021533796A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| JP2024515560A5 (https=) | ||
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| CN114829405B (zh) | 抗bcma/抗4-1bb双特异性抗体及其用途 | |
| JP2022513729A5 (https=) | ||
| JP2021529524A5 (https=) | ||
| JP2023546758A5 (https=) |